Developing new treatments for high-risk neuroblastoma
Pre-clinical efficacy and biomarker studies of ALK, MAPK and MDM2-p53 inhibitor combinations in neuroblastoma
Developing a blood test to help identify high risk Wilms tumours
Circulating molecular biomarkers for earlier identification of high risk Wilms tumour
Discovering biomarkers in high grade glioma to help find targeted treatments
Identifying the metabolic ‘Achilles Heel’ of childhood brain cancers
Improving our understanding of the genetics of neuroblastoma
Understanding neuroblastoma heterogeneity: genetic studies of circulating neuroblastoma tumour cells
Developing better and safer medicines for children with leukaemia
Screening for novel drug combinations in childhood B-cell acute lymphoblastic leukaemia
Improving treatment and reducing side effects for children with B-cell NHL
Identification of new drug targets to improve treatment options and reduce treatment-related toxicity for children diagnosed with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
Can a carbohydrate restricted diet help treat childhood brain tumours?
In vitro evaluation of the potential of glucose restriction as an adjuvant therapy for paediatric brain tumours
Investigating a new way of delivery drugs to the site of childhood brain tumours
Brain distribution models to select polymer-delivered drugs for the treatment of childhood brain cancers